Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

LSK BioPharma

Request full access

Health care product development company

Salt Lake City, United StatesFounded 2005Biotech & Life Sciences

About LSK BioPharma

Elevar Therapeutics, operating in the biopharmaceutical sector, focuses on the clinical development of innovative therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates: Rivoceranib (Apatinib), a VEGFR-2 inhibitor showing clinical efficacy in various solid tumors, and a BTK/JAK3 inhibitor with potential applications in hematologic malignancies and rheumatoid arthritis. Elevar Therapeutics serves patients with solid tumor cancers such as gastric, colorectal, adenoid cystic carcinoma, and hepatocellular carcinoma. The company operates globally, holding worldwide rights for Rivoceranib, excluding China, and has partnered for development and marketing in South Korea. Elevar Therapeutics generates revenue through the development, licensing, and commercialization of its drug candidates, aiming for regulatory approvals and market entry. The business model is centered around advancing clinical trials, securing regulatory approvals, and forming strategic partnerships to bring their therapies to market.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2005
Headquarters
Salt Lake City, United States
Employees
2
Open positions
None listed
Dealroom signal
22.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jul 2018 $20M $80M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

LSK BioPharma website traffic

Latest recorded traffic for LSK BioPharma is 0 monthly website visits. LSK BioPharma's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

LSK BioPharma in the Salt Lake City ecosystem

Live from Dealroom

The LSK BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Salt Lake City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about LSK BioPharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See LSK BioPharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.